Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.77 |
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | CASP3 | P42574 | 2/20 | 0.77 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.77 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268457 | 0.88 | MEN1 (0.65) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL15653078 | 0.87 | MEN1 (0.59) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL2272501 | 0.86 | MAPT (0.67) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL2272602 | 0.85 | DDX3X (0.55) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL4442005 | 0.83 | KMT2A (1.00) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL15652100 | 0.83 | KMT2A (0.73) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL2270208 | 0.81 | SAE1 (0.63) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL2269748 | 0.80 | RAB9A (0.63) | MAPTMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL15652393 | 0.79 | MEN1 (0.48) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL15651170 | 0.79 | CA1 (0.54) | MAPTMEN1KMT2ACASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-8420824-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8410286-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-7989439-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2011-08-02 | — | — | US | disclosed |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | MAPT 2805/4885MEN1 2480/4885KMT2A 2593/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 501/4885MEN1 1218/4885KMT2A 1345/4885 |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | CYP4B1, ADORA1, CYP1B1 | MAPT 2843/4885MEN1 2340/4885KMT2A 2544/4885 |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | MAPT 2805/4885MEN1 2480/4885KMT2A 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.